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https://doi.org/10.1016/j.stemcr.2019.04.022SUMMARYHuman embryonic stem cells (hESCs) are instrumental in characterizing themolecularmechanisms of human vascular development and
disease. Bonemorphogenetic proteins (BMPs) play a pivotal role in cardiovascular development inmice, but their importance for vascular
cells derived fromhESCs has not yet been fully explored. Here, we demonstrate that BMP9 promotes, via its receptor ALK1 and SMAD1/5
activation, sprouting angiogenesis of hESC-derived endothelial cells. We show that the secreted angiogenic factor epidermal growth fac-
tor-like domain 7 (EGFL7) is a downstream target of BMP9-SMAD1/5-mediated signaling, and that EGFL7 promotes expansion of endo-
thelium via interference with NOTCH signaling, activation of ERK, and remodeling of the extracellular matrix. CRISPR/Cas9-mediated
deletion of EGFL7 highlights the critical role of EGFL7 in BMP9-induced endothelial sprouting and the promotion of angiogenesis. Our
study illustrates the complex role of the BMP family in orchestrating hESC vascular development and endothelial sprouting.INTRODUCTION
Human embryonic stem cells (hESCs) are pluripotent and
therefore offer opportunities to investigate early human
development, model genetic diseases, and provide ap-
proaches to regenerative medicine. Thorough understand-
ing of vascular differentiation of hESCs will yield new
insights into how human vasculature develops and regen-
erates and lead to improved methods for producing
vascular cells for transplantation. Gene ablation in mice
has shown that the transforming growth factor b (TGF-b)
family, which also includes bone morphogenetic proteins
(BMPs), nodal, and activin, plays a fundamental role
in mesodermal development and vascular commitment.
Mutations in Endoglin and ALK1 have been linked to a
human vascular disorder, hereditary hemorrhagic telangi-
ectasia (HHT1 and HHT2, respectively), often resulting in
arteriovenous malformation (AVM) (Larrivee et al., 2012;
Lebrin et al., 2010). Also, mutations in the BMP type II
receptor gene are responsible for pulmonary arterial hyper-
tension (PAH) (Morrell et al., 2016).
TGF-b, activin, and nodal all activate SMAD2/3 to pro-
mote hESC self-renewal (Vallier et al., 2005). BMPs activate
SMAD1/5, which upregulate the expression of ID proteins
(inhibitors of DNA) that in turn inhibit bHLH transcription
factors (Hollnagel et al., 1999). Data on the role of the BMP
family in mediating the vascular commitment of hESCs is
sparse. Vascular cells have a mesoderm origin. BMP4
induces mesodermal differentiation and patterning and
promotes epithelial to mesenchymal transition (EMT) in1250 Stem Cell Reports j Vol. 12 j 1250–1259 j June 11, 2019 j ª 2019 The A
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It is well known that vascular endothelial growth factor
(VEGF) also plays a pivotal role in vascular differentiation.
Vascular expansion of hESC-derived endothelial cells (ECs)
can be induced by inhibition of the TGF-b/SMAD2/3
pathway (James et al., 2010). The BMP9/ALK1/SMAD1/5
pathway has been studied intensively in ECs and in mouse
ESC-derived ECs (reviewed in Goumans et al., 2017). The
fundamental mechanism by which BMP9/ALK1 signaling
can induce or inhibit angiogenesis is, however, still unclear
and presumably context dependent. This pathway has so
far not been studied in the process of differentiation of
hESC toward vascular cells.
The BMP effectors SMAD1/5 have a pivotal role in stalk
cell competence by regulating ECmigration and activating
the target genes of the NOTCH intracellular domain
(NICD) in stalk cells in mice (Moya et al., 2012). In addi-
tion, ALK1 signaling inhibits angiogenesis inmice by coop-
erating with the NOTCH pathway (Larrivee et al., 2012).
The molecular mechanism driving differential expression
of target genes in tip and stalk cells remains unclear
although several NICD-dependent genes are also BMP-
induced SMAD1/5 targets as shown by chromatin immu-
noprecipitation sequencing (ChIP-seq) studies in human
ECs (Morikawa et al., 2011). ID proteins are targets of
BMP-SMAD signaling that play a crucial role in deter-
mining the two EC types during the angiogenic phase
(Itoh et al., 2004; Moya et al., 2012).
Epidermal growth factor-like domain 7 (EGFL7) is a






Figure 1. Expansion and Sprouting of hESC-ECs Is Induced by BMP9 Signaling
(A) Schematic workflow of hESC-EC differentiation using (1) spin EBs and (2) monolayer.
(B) EBs generated from hESC were treated according to the protocol described in (A) with a special focus on BMP9 and SB-431542 (ALK4/
5/7 inhibitor) treatment. VEGF, control. After 9 days EBs were embedded in collagen I and evaluated 24 h later. Scale bar, 50 mm.
(C) Quantification of the sprouts by Wimasis (www.wimasis.com) for both length and area of the sprouts from three different experiments.
The error bars represent SD. *p < 0.05.
(D) Nine-day-old EBs embedded in collagen I were stained with antibody against ID1. Scale bar, 300 mm.
(legend continued on next page)
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on ECs. Expression of EGFL7 is highest in proliferating
vasculature and regulates tubulogenesis in zebrafish and
vascular patterning and integrity in mice (Nichol and
Stuhlmann, 2012). Interestingly, microRNA-126, an EC-
specific miRNA, resides in intron 7 of the EGFL7 gene and
regulates vascular integrity via the VEGF regulators SPRED1
and PIK3R2 (Fish et al., 2008; Wang et al., 2008). Ectopic
EGFL7 interacts with the extracellular domain of NOTCH
and as a result, functions as an antagonist of NOTCH acti-
vation (Schmidt et al., 2009). Here, we used hESCs as a
model for human vascular commitment to study the un-
derlyingmolecular mechanisms of BMP9 in vascular devel-
opment and disease. We demonstrate that BMP9/ALK1/
SMAD1/5-induced endothelial sprouting critically depends
on EGFL7. We link the BMP signaling pathway for the first
time with EGFL7.RESULTS
BMP9 Induces Expansion and Sprouting of hESC-
Derived Vascular Cells
Vascular differentiation of hESCs was obtained in cells that
were either forced by centrifugation to aggregate into
embryoid bodies (EBs) or inmonolayer cultures (Figure 1A).
To induce mesodermal differentiation, basic fibroblast
growth factor (bFGF), BMP4, ActivinA, the GSK3 inhibitor
CHIR99021, and VEGF165 were added to the hESCs. Three
days later, vascular expansion of mesodermal cells was
induced with VEGF alone or supplemented with either
SB-431542 (ALK4/5/7 inhibitor) or BMP9 under VEGF con-
ditions. The specificity of SB-431542 was shown by down-
regulation of SMAD7 and PAI-1 (Figures S1A and S1B). To
study the effect of BMP9 on the properties of the hESC-
ECs, EB sprouting was induced in collagen I and evaluated
on day 10; sprouting induced by only VEGF was modest.
Interestingly, SB-431542-treated EBs formed sheet-like
structures that were unable to invade the collagen, whereas
BMP9-treated EBs underwent extensive sprouting (Fig-
ure 1B and Videos S1, S2, and S3). The total sprout length
and the total area covered by the sprouts was increased
by 50%, respectively, compared with the VEGF control
condition (Figure 1C). ID1 is a downstream target of
BMP-SMAD1/5 signaling and promotes angiogenesis (Ly-
den et al., 1999; Valdimarsdottir et al., 2002). ID1 expres-
sion was investigated in endothelial outgrowth of hEBs.
BMP9 treatment of hEBs upregulated ID1 specifically in
the sprouts (Figure 1D). ID1 expression was elevated in(E) EBs were stimulated for mesodermal and vascular differentiation,
nabeads. CD31+ cells were seeded on Matrigel (growth factor reduced)
cells were stained for VE-Cadherin and pSMAD2/3 (first row), Endoglin
bar, 100 mm.
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those were unable to invade the collagen, which may be
due to an increase in stalk cells at the expense of tip cells.
Subsequently, CD31+ cells were used in a tube-like forma-
tion assay on Matrigel-coated chamber slides. BMP9 treat-
ment resulted in enhanced tube-like formation compared
with untreated and SB-431542-treated CD31+ cells (Fig-
ure 1E). Consistent with the increased tube-like formation
following BMP9 treatment, these cells were also enriched
for the endothelial markers VE-Cadherin and Endoglin,
whereas the smooth muscle differentiation marker aSMA
was undetectable. Taken together, BMP9 stimulation pro-
motes tube formation and angiogenic sprouting in hESC-
derived ECs.ALK1 Mediates the BMP9-Induced Sprouting of ECs
Derived from hESCs
The high-affinity receptor for BMP9 is the endothelial-spe-
cific ALK1 receptor (David et al., 2007), which becomes ex-
pressed at day 3 during hESC differentiation (Poon et al.,
2006). To study whether BMP9-induced hESC-derived
endothelial sprouting is dependent on ALK1, we used the
neutralizing anti-human ALK1 antibody PF-03446962,
which has been applied in phase I and II of a clinical trial
for cancer patients (Hu-Lowe et al., 2011; Necchi et al.,
2014). BMP9-treated EBs resulted in the highest yield of
angiogenic sprouting, which was robustly reduced using
the anti-human ALK1 antibody (Figure 2A). hESC-ECs
were harvested at day 10 and lysed for western blot anal-
ysis. SMAD1/5 activation was present in BMP9-treated
hESC-ECs but absent in anti-human ALK1 antibody-
treated cells (Figure 2B). Based on our observations, we
overexpressed constitutively active (ca) or dominant-nega-
tive (dn) forms of ALK1 in hESC-derived mesodermal cells
(day 3) under VEGF conditions for a further 6 days (Fig-
ure 2D). Then, cells were seeded on Matrigel, and tube-
like formation was assessed. Only caALK1 overexpressing
cells formed prominent tube-like structures (Figure 2C),
which further supported the role for BMP9/ALK1-induced
expansion and sprouting of hESC-ECs.EGFL7 Is a Direct Target Gene of BMP9 and Regulates
NOTCH and ERK Signaling
Proliferating ECs are enriched in ALK1 and EGFL7 expres-
sion (Parker et al., 2004; Suzuki et al., 2010). Yet, these
two endothelial-specific proteins have not been linked
directly. We hypothesized that EGFL7 is a downstreamdissociated after 10 days, and CD31+ cells were isolated using Dy-
and treated with either BMP9 or SB-431542 for 12 h. After fixation,





Figure 2. BMP9 Induces hESC-Derived Vascular Expansion and Endothelial Sprouting via ALK1
(A) EBs were embedded in collagen and treated with either IgG (control) or the anti-human ALK1 neutralizing antibody PF-03446962
(Pfizer). Lasso highlights angiogenic sprouting area. Scale bar, 50 mm. Sprout area quantified on the right (ImageJ) from three different
experiments. The error bars represent SD. **p < 0.01, ***p < 0.001.
(legend continued on next page)
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target of the BMP9/ALK1 axis in hESC-ECs. This was sub-
stantiated by SMAD1/5 ChIP-seq data in human umbilical
vein endothelial cells (HUVECs) treated with BMP9 for
90 min (Morikawa et al., 2011, #2920), which showed
five SMAD1/5 binding sites in the EGFL7 gene locus,
compatible with EGFL7 being a direct target of BMP9-
SMAD1/5 signaling (Figure 3A). Moreover, EGFL7 expres-
sion was induced upon BMP9 treatment of hESC-ECs
compared with the VEGF control condition (Figure 3B).
Accordingly, overexpression of caALK1 resulted in the up-
regulation of EGFL7 (Figures 3C and 3D). The adenovirally
infected ALK constructs were verified with respect to
SMAD1/5 and SMAD2/3 phosphorylation and the expres-
sion of the downstream targets ID1, SMAD7, and PAI-1
(Figures S1C–S1E).
To understand the function of EGFL7 in human vascular
sprouting, the CRISPR-Cas9 technique was used to knock
out EGFL7. Three different CRISPR guide RNAs (gRNAs)
that bind to three different exons within the EGFL7 gene
were used to create a homozygous knockout in HUVECs
(Figure S2A). A functional EGFL7 knockout in hESCs was
not achieved possibly because of an essential role of
EGFL7. High cleavage activity (28%) was obtained in the
T7EI assay for both gRNA1 and gRNA3, whereas gRNA2
exhibited no cleavage activity in HUVECs (Figure S2B). A
homozygous 1 bp deletion (Figure 3E), precisely where
Cas9 was expected to cleave the dsDNA, was generated in
exon 6, which resulted in a frameshift and therefore in a
knockout of EGFL7 (EGFL7/) using gRNA1. The lack of
EGFL7 was confirmed by western blot using an EGFL7 anti-
body recognizing the whole protein (Figure 3F). The
expression levels of both miR-126-5p and miR-126-3p,
which are encoded in the intronic 7 sequence of EGFL7,
were not affected in the EGFL7/ HUVECs (Figure S2C).
In addition, EGFL7/ cells showed comparable levels
of the endothelial marker CD31 as the wild-type (WT)
HUVECs (Figures S2D and S2E). The proliferation rate was
slower in EGFL7/ cells (data not shown).
Blood vessel formation is orchestrated by cross-talk be-
tween the BMP, NOTCH, and VEGF signaling pathways.
Ectopic EGFL7 can interact with the extracellular domains
of NOTCH1–4 and thus functions as an antagonist of
NOTCH activation that downregulates expression of
NOTCH target genes (Schmidt et al., 2009). Ectopic
EGFL7-NOTCH interactions result in a hyper-angiogenic
response in mice (Nichol et al., 2010). Expression analysis(B) Western blot of protein lysate from BMP9-induced EBs treated w
periments.
(C) hESC-derived mesodermal cells were adenovirally infected with dif
vascular commitment. Cells were seeded on Matrigel and tube-like fo
negative. Scale bar, 100 mm.
(D) Western blot of protein lysate from the adenovirally infected cell
1254 Stem Cell Reports j Vol. 12 j 1250–1259 j June 11, 2019of HES1 and HEY1 in HUVECs showed significant upregu-
lation of these genes in EGFL7/ cells (Figure 3G), which
is consistent with the above-mentioned studies (Nichol
et al., 2010; Schmidt et al., 2009). Moreover, HES1 and
HEY1 expression in EGFL7+/ cells was half that observed
in EGFL7/ cells (Figure S2F). Along the same lines,
BMP9 downregulated HES1 and HEY1 in hESC-ECs (Fig-
ure 3H), suggesting EGFL7 as a bridge between BMP9 and
NOTCH signaling regulation.
In our study, the phosphorylation status of ERK1/2
was used as a readout for activation of the MAP kinase
pathway. We found that EGFL7/ cells exhibit attenuated
ERK1/2 phosphorylation compared with WT HUVECs
(Figure 3I). Interestingly, the negative regulators of the
VEGF-induced MAPK pathway and phosphatidylinositol
3-kinase, SPRED1, and PIK3R2, respectively (Fish et al.,
2008), were significantly upregulated in EGFL7/
HUVECs (Figure 3J), suggesting a regulatory role for
EGFL7 in enhancing VEGF/ERK signaling.
Assessment of mRNA and protein levels by immuno-
staining analysis and western blotting revealed decreased
expression of the ALK1/SMAD1/5 targets ID1 and
TMEM100 in EGFL7/ (Figures S2E and S3A–S3C), which
could be explained by a positive feedforward loop of the
BMP9-induced EGFL7 (Itoh et al., 2004).
Taken together, EGFL7 expression is dependent on
BMP9/ALK1 signaling and has inhibitory effects on
the NOTCH pathway but positive effects on the VEGF/
ERK pathway, resulting in the endothelial sprouting
phenotype.
BMP9-Induced EGFL7 Regulates Extracellular
Remodeling and Is Necessary for Tube Formation
To further decipher the importance of EGFL7 in BMP9-
treated hESC-ECs, short hairpin EGFL7 (shEGFL7) was len-
tivirally infected in hESC-derived mesodermal cells (day 3)
and EC differentiation was induced in a monolayer culture
for 7 days (Figure 4A). Then, cells were seeded on Matrigel
and tube-like formation was assessed after 24 h. BMP9
enhanced tube formation in shControl compared with un-
treated cells, whereas BMP9 was unable to do so in EGFL7
knockdown cells (Figures 4A and 4B).
Angiogenesis is regulated by dynamic interaction be-
tween ECs and the extracellular matrix (ECM) (ten Dijke
and Arthur, 2007; Goumans et al., 2017). EGFL7 is a
secreted protein and is tightly associated with theith hALK1 ab or IgG as a control, representing three different ex-
ferent ALK receptor constructs and then induced with VEGF toward
rmation assessed (n = 3). ca; constitutively active, dn; dominant-
s used in (C). The ALK1 constructs are HA tagged. LacZ, control.
Figure 3. The BMP9/ALK1/SMAD1/5 Pathway Directly Binds to and Induces EGFL7 Expression, which Regulates NOTCH and ERK
Signaling
(A) Visualization of the EGFL7 gene locus and the results of SMAD1/5 ChIP-seq in HUVECs. Red peaks represent SMAD1/5 binding sites. The
asterisk depicts the strongest binding site.
(B) Western blot of EGFL7 after treatment of hESC-ECs with BMP9 or SB-431542. EGFL7 expression was normalized to actin (right panel).
PB-EGFL7, PiggyBac-EGFL7 overexpression used as a positive control. Quantification of western blot bands from three independent ex-
periments on the right (ImageJ). The error bars represent SD. **p < 0.01, ***p < 0.001 using unpaired Student‘s t test.
(C) Western blot of protein lysate from the ALK adenovirally infected hESC-ECs. EGFL7 expression and actin as a loading control.
(D) qRT-PCR of EGFL7 after adenoviral infection of ALK constructs in hESC-ECs (normalized to human ARP usingDDCt) from three different
experiments. The error bars represent SD.
(E) 1 bp deletion was generated in both alleles of the EGFL7 gene using CRISPR and gRNA1 in HUVECs. The 1 bp deletion is highlighted with
an orange box; the sgRNA1 binding site is underlined.
(legend continued on next page)
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interstitial ECM. Moreover, fibronectin (FN) facilitates
EGFL7 deposition (Schmidt et al., 2007). We investigated
the FN expression in conditions of EGFL7 deficiency and
BMP9 induction. The expression of FN was significantly
reduced in EGFL7/ HUVECs at both mRNA and protein
levels as detected by qPCR, western blotting, and immuno-
staining analyses (Figures 4C–4E). FN was significantly up-
regulated in BMP9-treated hESC-ECs (Figure 4F).
Taken together, EGFL7 is necessary for BMP9-induced
tube-like formation of hESC-ECs. FN expression is depen-
dent on EGFL7. Whether EGFL7 regulates FN at the post-
transcriptional level or as a secreted form is unknown.DISCUSSION
We demonstrate that the BMP9/ALK1 cascade promotes
sprouting of hESC-ECs. Moreover, we found evidence
that the extracellular protein EGFL7 is a target gene of
BMP9-induced SMAD1/5 and a key player in fine-tuning
the pro- and anti-angiogenic balance by mediating inhibi-
tion of the NOTCH pathway and enhancing VEGF/ERK
signaling. EGFL7 is also involved inmodulating expression
of ECM proteins as shown by the importance of EGFL7 for
FN expression (Figure S3D).
Here, we demonstrate that ID1 is induced in EBs treated
with the ALK4/5/7 inhibitor, SB-431542, but the cells ex-
pressing ID1 are incapable of invading the collagen matrix
in contrast to the BMP9-induced ID1 expression cells,
which are highly invasive. We suggest that this property
is acquired through the active involvement of EGFL7.
In the postnatal retina, EGFL7 antagonizes NOTCH
signaling, which results in a hyper-angiogenic response
(Nichol et al., 2010). Our study showed an upregulation
of NOTCH target genes in EGFL7/ HUVECs, indicating
that BMP9-induced expression of EGFL7 could mediate
the angiogenic effect by inhibiting NOTCH signaling.
This is in contrast to several publications where BMP9
has been shown to upregulate NOTCH target genes. How-
ever, BMP signaling synergizes with NOTCH and antago-
nizes NOTCH signaling at later time points, and our cells
are exposed to a long-term BMP9 treatment. Hence,
EGFL7 may be the candidate in fine-tuning this cross-talk.(F) Western blot of EGFL7 and actin expression from protein samples
positive control.
(G and H) qRT-PCR of the NOTCH target genes (HES1, HEY1) (normal
and untreated versus BMP9-treated hESC-ECs (H). Graphs represent o
**p < 0.01, ***p < 0.001 using unpaired Student‘s t test.
(I) Western blot of phosphorylated ERK1/2 and actin expression (loa
(J) qRT-PCR of the negative regulators of the VEGF- induced MAPK
(normalized to human ARP using DDCt) in WT and EGFL7/ HUVEC
Student‘s t test.
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BMP9 in association with the upregulation of NOTCH
target genes used a high dose of BMP9 (10 ng/mL) (David
et al., 2007; Larrivee et al., 2012), whereas in this study
we use 1 ng/mL BMP9. TGF-b has a biphasic effect on
ECs, being pro-angiogenic at low dose (via SMAD1/5) and
anti-angiogenic at high dose (via SMAD2/3) (Goumans
et al., 2002). A biphasic effect could also apply to BMP9,
but additional work is needed to unravel BMP9 dose depen-
dency on NOTCH signaling and its effect on blood vessel
formation.
In addition, secreted EGFL7 is involved in overall ECM
composition and remodeling by direct binding of other
ECM proteins in ECs (Schmidt et al., 2007). Here, we
demonstrate a dramatic decrease in the expression of FN
in EGFL7/ HUVECs and an induction of FN expression
upon BMP9 treatment. EGFL7 can bind to integrins in
ECs (Nikolic et al., 2013), but additional work is needed
to study in detail the involvement of BMP9-induced
EGFL7 in ECM interactions.
Defects in BMP signaling in the vascular bed result in dis-
eases such as HHT and PAH. Elucidating the signaling cas-
cades that have instructive roles in vasculogenesis and
angiogenesis is therefore of great importance. Moreover,
improving vascular development in culture can feedfor-
ward the use of organoids as a source for large engineered
tissues.EXPERIMENTAL PROCEDURE
Cell Culture of hESCs and HUVECs
The Icelandic Bioethics committee has approved the appli-
cation of hESC lines for our research (permit 05-079). hESC
linesHES2andH1 (WiCell Research Institute,Madison,WI)
were obtained as trypsin-adapted variants from the Keller
laboratory. hESC lines were routinely cultured on a mono-
layer of mitomycin C-treated primary mouse embryonic
fibroblasts (MEFs CF-1 strain, CellSystems). Medium
consisted of 3/4 DMEM/F12 (Invitrogen), supplemented
with 20% KnockOut Serum Replacement (Invitrogen), 1%
penicillin/streptomycin (Invitrogen), 200 nM L-glutamine
(Invitrogen), 1% non-essential amino acids (Invitrogen),of WT and EGFL7/ HUVECs. PB-EGFL7 overexpression used as a
ized to human ARP using DDCt) in WT and EGFL7/ HUVECs (G)
ne of three independent experiments. The error bars represent SD.
ding control) from protein samples of WT and EGFL7/ HUVECs.
pathway and phosphatidylinositol 3-kinase SPRED1 and PIK3R2






Figure 4. EGFL7 Affects Extracellular Matrix Proteins
(A) hESC-derived mesodermal cells were lentivirally infected with shEGFL7 or shControl constructs in pLKO.1 plasmid and selected on
puromycin and induced toward vascular cells according to protocol. Two shRNA-EGFL7 were combined for infection. Cells were seeded on
Matrigel and tube-like formation assessed. sh, short hairpin. Scale bar, 100 mm. Number of tubes and junctions were quantified (ImageJ)
from three independent experiments. The error bars represent SD. *p < 0.05.
(B) Western blot of EGFL7 knockdown. EGFL7 expression and actin (used as a loading control). PB-EGFL7, PiggyBac-EGFL7 overexpression
as a positive control.
(C) Immunofluorescent staining ofWT and EGFL7/HUVECs against fibronectin (FN) and TOPRO-3 (blue) nuclear staining. Scale bar, 100mm.
(legend continued on next page)
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55 mM 2-mercaptoethanol (Invitrogen) mixed with 1/4
mTesR1 (STEMCELL Technologies). For mesodermal and
vascular differentiation, hESCs were cultured in BPEL me-
dium (Ng et al., 2008) feeder free on Matrigel-coated (BD)
(diluted 1:100 inDMEM/F12without supplements) culture
dishes. TrypLE (Invitrogen) was used to dissociate the cells
for splitting and expansion. The HUVECs were cultured in
EGM-2 medium (Lonza) on 0.1% gelatin-coated cultures
flasks.
Statistical Analysis
Experiments were conducted in triplicate and data are pre-
sented as means ± SD. Significance of differences was
measured by an unpaired Student’s t test. The following
p values were considered statistically significant: *p <
0.05, **p < 0.01, ***p < 0.001.
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